Heron Therapeutics, Inc.

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2022 Earnings Conference. As a reminder, this conference is being recorded. Now, I would like to turn the call over to David Zacharis, Executive Vice President, Chief Operating Officer. Please proceed.

Thank you, Dennis. Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Cork, Chief Executive Officer and Chairman, John Poynan, President and Chief Commercial Officer, and Kimberly Manhart, Executive Vice President of Drug Development and Board Director. For those of you participating via conference call, the slides are made available via webcast. You can also be accessed by going to the Investor Relations page of our website following conclusion of today's call. Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Heron's future expectations, plans, prospects, corporate strategy, and performance, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our filings of the SEC. In addition, any forward-looking statements represent our views only as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. Now, I'll turn the call over to Barry.

Thank you, David.